Search Results

Your search matched 9 results

#1

Why the New CMS Oncology Model is an Inflection Point in Advancing Health Equity | Blog

On July 1st, The Centers for Medicare & Medicaid Services, through its Center for Medicare & Medicaid Innovation (CMMI), announced its newest voluntary oncology payment model, Enhancing Oncology Model (EOM).

#2

ICER’s Final Evidence Report on bluebird bio’s Gene Therapy, beti-cel, Highlights Alternative Payment Model for One-Time Curative Treatment | Blog

In July, the Institute for Clinical and Economic Review (ICER) published its final evidence report for bluebird bio’s Zynteglo (betibeglogene autotemcel or “beti-cel”) for the treatment of beta thalassemia, a rare, debilitating blood disorder.

#3

Biosimilar Elimination Red Tape Act | Blog

In November 2022, Sen.

#4

State-Level Drug Pricing Policy Accelerating: Life Sciences Companies Can Contextualize Value & Access to Policymakers | Blog

While federal drug pricing reform in the Build Back Better Act (BBBA) is stalled at the Senate, states are taking the issue into their own hands.

#5

January Drug Price Increases Fuel Continued Scrutiny; Underscores Need to Communicate Pricing Factors | Blog

With a global pandemic, rising inflation, and continued political pressures, drug pricing will undoubtedly remain a big focus in 2022.

#6

What the lecanemab Approval Means for the Life Science Industry | Blog

The Food and Drug Administration (FDA) approved Alzheimer’s disease (AD) drug lecanemab through its accelerated approval program.

#7

What the CMS National Coverage Decision Means for the Life Science Industry   | Blog

What the CMS National Coverage Decision Means for the Life Science Industry  

#8

ICER Policy Proposals for Orphan Drug Pricing | Blog

The Institute for Clinical and Economic Review (ICER) recently published the white paper “The Next Generation of Rare Disease Drug Policy: Ensuring Both Innovation and Affordability.”

#9

Health Equity, Real-World Evidence: A Trend to Watch | Blog

The Biden administration cited health equity as one of its top 5 health priorities in a Health Affairs blog.